Amylyx Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
Amylyx Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release on August 6, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02), which reports results of operations and financial condition.

Key Details

• Press release dated August 6, 2026 was furnished as Exhibit 99.1 to the Form 8‑K.
• The results cover the quarter ended June 30, 2026.
• The company states the furnished information is “not deemed ‘filed’” under Section 18 of the Exchange Act (limits certain liabilities).
• The Form 8‑K was signed by CFO James M. Frates on August 6, 2026.

Why It Matters
This filing signals that Amylyx has released its latest quarterly earnings and related financial information; investors should review the press release (Exhibit 99.1) for revenue, earnings, cash position and any guidance. Note that because the release was furnished rather than filed, it is treated differently for legal liability—investors should also watch for the company’s formal periodic filings (e.g., Form 10‑Q) for complete audited/disclosed financial statements and risk discussion.